This phase I/II trial is evaluating a combination of two intravenous drugs (Isatuximab and Cemiplimab) for patients with multiple myeloma that has got worse or not responded to prior treatment.
This trial is treating patients with multiple myeloma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma
Commercial Sponsor
Sanofi Aventis
Summary
The primary aim of this trial is to assess the safety and tolerability of a combination of two drugs (Isatuximab and Cemiplimab), and compare the overall response of this combination with isatuximab alone, in patients with relapsed/refractory multiple myeloma.
Recruiting Hospitals Read More